Research map: Reported Characteristics of Anaphylaxis Associated With Glatiramer Acetate: A Pharmacovigilance Analysis of the FDA and Canadian Databases

Back to the article

Papers in this map

  1. Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis · Jeffrey A. Cohen · 2010 · 2217 citations · Cited by this paper
  2. Glatiramer acetate-related anaphylaxis characteristics · 2026 · Cites this paper
  3. Using a N ano BRET ‐Based Ligand‐Binding Assay at the β 2 ‐Adrenoceptor for Undergraduate Pharmacology Education · 2026 · Related
  4. The reporting odds ratio and its advantages over the proportional reporting ratio · Kenneth Jay Rothman · 2004 · 1120 citations · Cited by this paper
  5. Magnitude, Preventability, and Determinants of Adverse Drug Reactions Among Hospitalized Obstetric Patients in Ethiopia: A Prospective Observational Study · 2026 · Related
  6. Data Mining of the Public Version of the FDA Adverse Event Reporting System · Toshiyuki Sakaeda · 2013 · 1057 citations · Cited by this paper
  7. Potent and Sustained Lowering of Serum Uric Acid by YJH ‐012‐D, a G al NA c‐Conjugated si RNA Targeting Xanthine Dehydrogenase · 2026 · Related
  8. A Pilot Trial of Cop 1 in Exacerbating–Remitting Multiple Sclerosis · Murray B. Bornstein · 1987 · 463 citations · Cited by this paper
  9. A Prospective Study of Marsh PK ‐ PD Model and Schnider PK ‐ PD Model During Anesthesia Induction for Obese Patients Undergoing Elective Heart Surgery · 2026 · Related
  10. ECTRIMS / EAN guideline on the pharmacological treatment of people with multiple sclerosis · Xavier Montalbán · 2018 · 228 citations · Cited by this paper
  11. Deciphering the Functional Mechanisms of eIF3f in Tumors and Exploring Targeted Therapies · 2026 · Related
  12. A placebo‐controlled, double‐blind, randomized, two‐center, pilot trial of Cop 1 in chronic progressive multiple sclerosis · Murray B. Bornstein · 1991 · 173 citations · Cited by this paper
  13. A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Highly Selective NaV1.8 Inhibitor JKN2306 in Healthy Chinese Subjects · 2026 · Related
  14. Glatiramer acetate in multiple sclerosis: update on potential mechanisms of action · Cinthia Farina · 2005 · 138 citations · Cited by this paper
  15. Student and Graduate Perceptions of Their Development of the Core Attitudes From the British Pharmacological Society's Undergraduate Pharmacology Curriculum · 2026 · Related
  16. The mechanism of action of glatiramer acetate in multiple sclerosis and beyond · Rina Aharoni · 2012 · 123 citations · Cited by this paper
  17. Evaluating the Educational Value of Artificial Intelligence in Pharmacotherapy Education · 2026 · Related
  18. Time‐to‐onset analysis of amiodarone‐associated thyroid dysfunction · Sayoko Kinoshita · 2019 · 117 citations · Cited by this paper
  19. Impact of FCGR2A and FCGR3A Gene Variants on the Response to Rituximab in Patients With Glomerular Diseases · 2026 · Related
  20. Effects of oral glatiramer acetate on clinical and MRI-monitored disease activity in patients with relapsing multiple sclerosis: a multicentre, double-blind, randomised, placebo-controlled study · Massimo Filippi · 2006 · 81 citations · Cited by this paper
  21. The Relationship Between (Endo)cannabinoids, the Microbiome and Melanoma · 2026 · Related
  22. The Evolving Mechanisms of Action of Glatiramer Acetate · Thomas Prod’homme · 2018 · 80 citations · Cited by this paper
  23. A critical appraisal of treatment decisions in multiple sclerosis—old versus new · Bernd C. Kieseier · 2011 · 69 citations · Cited by this paper
  24. Adverse events with sacubitril/valsartan in the real world: emerging signals to target preventive strategies from the FDA adverse event reporting system · Milo Gatti · 2020 · 69 citations · Cited by this paper
  25. Acute Kidney Injury Associated With Remdesivir: A Comprehensive Pharmacovigilance Analysis of COVID-19 Reports in FAERS · Bin Wu · 2022 · 67 citations · Cited by this paper
  26. The impact of anti-TNFα agents on weight-related changes: new insights from a real-world pharmacovigilance study using the FDA adverse event reporting system (FAERS) database · Faizan Mazhar · 2021 · 66 citations · Cited by this paper
  27. Diagnosing, managing and preventing anaphylaxis: Systematic review · Debra de Silva · 2020 · 60 citations · Cited by this paper
  28. Emerging Toxicities of Antibody-Drug Conjugates for Breast Cancer: Clinical Prioritization of Adverse Events from the FDA Adverse Event Reporting System · Sara Cecco · 2024 · 51 citations · Cited by this paper
  29. New acute and chronic black holes in patients with multiple sclerosis randomised to interferon beta-1b or glatiramer acetate · Diego Cadavid · 2009 · 48 citations · Cited by this paper
  30. Severe anaphylactic reaction to glatiramer acetate with specific IgE · H. Rauschka · 2005 · 38 citations · Cited by this paper
  31. An update on anaphylaxis and urticaria · Margitta Worm · 2022 · 17 citations · Cited by this paper
  32. Management of immediate hypersensitivity reaction to glatiramer acetate · E. Amsler · 2017 · 9 citations · Cited by this paper

Source: OpenAlex (CC0)